

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: S. Jayaraman
Application No.: To be Assigned
Filed: Herewith
For: RATIONALLY DESIGNED THERAPEUTIC INTRAVASCULAR IMPLANT
COATING

Attorney Docket No.: 795-A03-004
Group Art Unit:
Examiner:

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56**

Commissioner for Patents
Alexandria, VA 22313

Sir:

In accordance with the duty of disclosure provisions of C.F.R. § 1.56, there is hereby provided certain information, which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.


A revised Form PTO/SB/08 listing all patents, publications, applications, or other information submitted for consideration is enclosed. Copies of the listed U.S. Patents and Published U.S. Patent applications are not being submitted pursuant to the USPTO's waiver of the requirement of 37 C.F.R. § 1.98(a)(2)(i). Enclosures accompanying this Information Disclosure Statement are: (a) copies of the cited foreign references (b) copies of cited articles.

No admission is made that the information cited in this Statement is, or is considered to be prior art, material to patentability nor a representation that a search has been made.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or certification is required.

Dated: 10/09/2003

Respectfully submitted,


Paul D. Bianco (Reg. No. 43,500)

Attorney for Applicant
Fleit, Kain, Gibbons, Gutman, Bongini & Bianco P.L.
601 Brickell Key Drive
Suite 404
Miami, Florida 33131
305-931-9620 (telephone)

Please type a plus sign (+) inside this box

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Approved for use under 17 CFR 200.91. GML 05/05/2001

Patent and Trademark Office, U.S. Department of Commerce

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>-Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)</p>				Complete If Known	
				Application Number	
				Filing Date	
				First Named Inventor	S. Jayaraman
				Group Art Unit	
				Examiner Name	
Sheet	2	of	8	Attorney Docket Number	795-A03-004
U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY
	AW	5,688,824		Williams	11-18-1997
	AX	5,728,710		Luengo	03-17-1998
	AY	5,837,313		Ding et al.	11-17-1998
	AZ	5,891,507		Jayaraman	04-06-1998
	BA	5,997,468		Wolff et al.	12-07-1999
	BB	6,046,328		Schonharting et al.	04-04-2000
	BC	6,051,596		Badger	04-18-2000
	BD	6,071,305		Brown et al.	06-06-2000
	BE	6,129,705		Grantz	10-10-2000
	BF	6,143,037		Goldstein et al.	11-07-2000
	BG	6,153,252		Hossainy et al.	11-28-2000
	BH	6,197,781		Guitard et al.	03-06-2001
	BI	6,203,551		Wu	03-20-2001
	BJ	6,231,600		Zhong	05-15-2001
	BK	6,238,430		Klumb et al.	05-29-2001
	BL	6,239,102		Tiemessen	05-29-2001
	BM	6,239,124		Zenke et al.	05-29-2001
	BN	6,245,104		Alt	06-12-2001
	BO	6,248,127		Shah et al.	06-19-2001
	BP	6,251,136		Guruwaiya et al.	06-26-2001
	BQ	6,254,634		Anderson et al.	07-03-2001
Examiner				Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)				Complete If Known	
				Application Number	
				Filing Date	
				First Named Inventor	S. Jayaraman
				Group Art Unit	
				Examiner Name	
Sheet	1	of	8	Attorney Docket Number	795-A03-004
U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY
	AA	3,903,071		Holmes	09-02-1975
	AB	4,650,803		Stella et al.	03-17-1987
	AC	5,100,899		Calne	03-31-1992
	AD	5,212,155		Calne	05-18-1993
	AE	5,221,740		Hughes	06-22-1993
	AF	5,282,785		Shapland et al.	02-01-1994
	AG	5,283,257		Gregory et al.	02-01-1994
	AH	5,286,254		Shapland et al.	02-15-1994
	AI	5,286,731		Caufield et al.	02-15-1994
	AJ	5,288,711		Mitchell et al.	02-22-1994
	AK	5,308,847		Calne	05-03-1994
	AL	5,318,895		Kahn et al.	06-07-1994
	AM	5,403,833		Calne	04-04-1995
	AN	5,457,113		Cullinan et al.	10-10-1995
	AO	5,461,058		Calne	10-24-1995
	AP	5,496,832		Armstrong	03-05-1996
	AQ	5,508,397		Or et al.	04-16-1996
	AR	5,516,781		Morris et al.	05-14-1996
	AS	5,519,042		Morris et al.	05-21-1996
	AT	5,624,946		Williams	04-29-1997
	AU	5,646,160		Morris et al.	07-08-1997
	AV	5,674,732		Nishida et al.	10-07-1997
Examiner				Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

8

Compl te if Known

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

S. JAYARAMAN

Attorney Docket Number

795-A03-004

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	FB	D. BUNJES, C. HARDT, M WILLINGHOFF and, H WAGNER, CYCLOSPORIN A MEDIATES IMMUNOSUPPRESSION OF PRIMARY CYTOTOXIC T CELL RESPONSES BY IMPAIRING THE RELEASE OF INTERLEUKIN 1 AND INTERLEUKIN 2, J. IMMUNOL. 1981, 11:657-661.	
	FC	J DIJOSEPH, E FLUHLER, J ARMSTRONG, M SHARR, and S SEHGAL, THERAPEUTIC BLOOD LEVELS OF SIROLIMUS (RAPAMYCIN) IN THE ALLOGRAFTED RAT, TRANSPLANTATION 1996, 62:1109-1112.	
	FD	B HAUSEN, K BOEKE, G BERRY, I BEGARRA, L BENET, U CHRISTIANS and R MORRIS, COADMINISTRATION OF NEORAL AND THE NOVEL RAPAMYCIN ANALOG, SDZ RAD, TO RAT LUNG ALLOGRAFT RECIPIENTS, TRANSPLANTATION 1999, 67:956-962.	
	FE	L TURKA, J DAYTON, G SINCLAIR, C THOMPSON, and B MITCHELL, GUANINE RIBONUCLEOTIDE DEPLETION INHIBITS T CELL ACTIVATION, J. Clin. Invest. 1991, 87:940-948.	
	FF	W SCHULER, R SEDRANI, S COTTENS, B HABERLIN, M SCHULZ, H SCHUURMAN, G ZENKER, H ZERWES, and M SCHREIBER, SDZ RAD, A NEW RAPAMYCIN DERIVATIVE, TRANSPLANTATION 1997, 64:36-42.	
	FG	H SCHUURMAN, J RINGERS, W SCHULER, W SLINGERLAND and M JONKER, ORAL EFFICACY OF THE MACROLIDE IMMUNOSUPPRESSANT SDZ RAD AND OF CYCLOSPORINE MICROEMULSION IN CYNOMOLGUS MONKEY KIDNEY ALLOTRANSPLANTATION, TRANSPLANTATION 2000, 69:737-742.	
	FH	J. SOUSA, A. ABIZAID, A. ABIZAID, F. FERES, I. PINTO, A. SEIXAS, R. STAICO, L. MATTOS, A. SOUSA, R. FALCICO, J. JAEGER, J. POPMA, P. SERRUYAS, M. COSTA, LACK OF NEOINTIMAL PROLIFERATION AFTER IMPLANTATION OF SIROLIMUS-COATED STENTS IN HUMAN CORONARY ARTERIES, CIRCULATION 2000, 102:r54-r57.	
	FI	C GREGORY, S KATZNELSON, S GRIFFEY, A KYLES and E BERRYMAN, FLUVASTATIN IN COMBINATION WITH RAD SIGNICANTLY REDUCES GRAFT VASCULAR DISEASE IN RAT CARDIAC ALLOGRAFTS, CIRCULATION 2001, 72:989-993.	
	FJ	R MORRIS, IMMUNOPHARMACOLOGY OF NEW XENOBIOTIC IMMUNOSUPPRESSIVE MOLECULES, SEMINARS IN NEPHROLOGY 1992, 12:304-314.	
	FK	J MEHILLI, A KASTRATI, W KOCH, C BOTTIGER, N VON BECKERATH, A SCHOMIG, RELATION BETWEEN TUMOR NECROSIS FACTOR (TNF) GENE POLYMORPHISMS AND THROMBOTIC EVENTS AND RESTENOSIS IN PATIENTS WITH CORONARY STENTING, ABSTRACT FROM ACCIS 2000 MEETING, 13A.	
	FL	R. KNIGHT, M. FERRARESSO, F. SERINO, S. KATZ, R. LEWIS, AND B.D. KAHAN, LOW-DOSE RAPAMYCIN POTENTIATES THE EFFECTS OF SUBTHERAPEUTIC DOSES OF CYCLOSPORINE TO PROLONG RENAL ALLOGRAFT SURVIVAL IN THE MONGREL CANINE MODEL, TRANSPLANTATION 1993, 55:947-949.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

8

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

S. JAYARAMAN

Attorney Docket Number

795-A03-004

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	FM	H SCHUURMAN, S COTTENS, S FUCHS, J JOERGENSEN, T MEERLOO, R SEDRANI, M TANNER, G ZENKE and W SCHULER, SDZ RAD, A NEW RAPAMYCIN DERIVATIVE, TRANSPLANTATION 1997, 64:32-35.	
	FN	B KAHAN, M MURGIA, J SLATION, and K NAPOLI, POTENTIAL APPLICATIONS OF THERAPEUTIC DRUG MONITORING OF SIROLIMUS IMMUNOSUPPRESSION IN CLINICAL RENAL TRANSPLANTATION, THERAPEUTIC DRUG MONITORING 1995, 17:672-675.	
	FO	R YATSCOFF, P WANG, K CHAN, D HICKS and J ZIMMERMAN, RAPAMYCIN: DISTRIBUTION, PHARMACOKINETICS, AND THERAPEUTIC RANGE INVESTIGATIONS, THERAPEUTIC DRUG MONITORING 1995, 17:666-671.	
	FP	H.U. SCHORLEMMER, F.R. SEILER, and R.R. BARTLETT, PROLONGATION OF ALLOGENEIC TRANSPLANTATION SKIN GRAFTS AND INDUCTION OF TOLERANCE BY LEFLUNOMIDE, A NEW IMMUNOSUPPRESSIVE ISOXAZOL DERIVATIVE, TRANSPLANTATIONS PROCEEDINGS 1993, 25:753-767.	
	FQ	D BRANISTEANU, C MATHIEU, R BOUILLON, SYNERGISM BETWEEN SIROLIMUS AND 1,25 DIHYDROXYVITAMIN D, IN VITRO AND IN VIVO, JOURNAL OF NEUROIMMUNOLOGY 1979, 79:138-147.	
	FR	B KAHAN, EFFICACY OF SIROLIMUS COMPARED WITH AZATHIOPRINE FOR REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION: A RANDOMISED MULTICENTRE STUDY, LANCET 2000, 356:194-202.	
	FS	B KLUGHERZ, G LLANOS, W LIEUALLEN, G. KOPLA, G PAPANDREOU, P NARAYAN, T LEVENGOOD, B SASSEEN, S ADELMAN, R FALOTICO, R WILENEIR, STENT-BASED DELIVERY OF SIROLIMUS FOR THE PREVENTION OF RESTENOSIS, ABSTRACT FROM ACCS 2000 MEETING.	
	FT	R SAUNDERS, M METCALFE, M NICHOLSON, RAPAMYCIN IN TRANSPLANTATION: A REVIEW OF EVIDENCE, KIDNEY INTERNATIONAL 2001, 59:3-16.	
	FU	R YATSCOFF, D LeGATT, and N KNETEMAN, THERAPEUTIC MONITORING OF RAPAMYCIN: A NEW IMMUNOSUPPRESSIVE DRUG, THERAPEUTIC DRUG MONITORING 1993, 15:478-482.	
	FV	S STEPKOWSKI, K NAPOLI, M WANG, X QU, T CHOU, and B KAHAN, EFFECTS OF THE PHARMACOKINETIC INTERACTION BETWEEN ORALLY ADMINISTERED SIROLIMUS AND CYCLOSPORINE ON THE SYNERGISTIC PROLONGATION OF HEART ALLOGRAFT SURVIVAL IN RATS, TRANSPLANTATION 1996, 62:986-994.	
	FW	B. HAUSEN, J. GUMMERT, G.J. BERRY, U. CHRISTIANS, N. SERKOVA, T. IKONEN, L. HOOK, F. LEGAY, W. SCHULER, M.H. SCHREIER, and R.E. MORRIS, PREVENTION OF ACUTE ALLOGRAFT REJECTION IN NONHUMAN PRIMATE LUNG TRANSPLANT RECIPIENTS, TRANSPLANTATION 2000, 69:488-496.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 8

Complete if Known

Application Number	
Filing Date	
First Named Inventor	S. JAYARAMAN
Group Art Unit	
Examiner Name	
Attorney Docket Number	795-A03-004

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	FX	S SEHGAL, RAPAMUNE (SIROLIMUS, RAPAMYCIN): AN OVERVIEW AND MECHANISM OF ACTION, THERAPEUTIC DRUG MONITORING 1995, 17:660-665.	
	FY	R MORRIS, MECHANISMS OF ACTION OF NEW IMMUNOSUPPRESIVE DRUGS, THERAPEUTIC DRUG MONITORING 1995, 17:564-569.	
	FZ	P KELLY, S GRUBER, F BEHBOD, and B KAHAN, SIROLIMUS, A NEW, POTENT IMMUNOSUPPRESSIVE AGENT, PHARMACOTHERAPY 1997, 17:1148-1156.	
	EA	G INGLE, T STEVENS, and C HOLT, SIROLIMUS: CONTINUING THE EVOLUTION OF TRANSPLANT IMMUNOSUPPRESSION, THE ANNALS OF PHARMACOTHERAPY 2000, 34:1044-1055.	
	EB	S MARX, A MARKS, BENCH TO BEDSIDE. THE DEVELOPMENT OF RAPAMYCIN AND ITS APPLICATION OF STENT RESTENOSIS, CIRCULATION 2001, 104:852-855.	
	EC	S.M. STEPKOWSKI and B.D. KAHAN, SYNERGISTIC ACTIVITY OF THE TRIPLE COMBINATION: CYCLOSPORINE, RAPAMYCIN, AND BREQUINAR, TRANSPLANTATION PROCEEDINGS 1993, 24:29-31.	
	ED	B KAHAN, M MURGIA, J SLATON, and K NAPOLI, POTENTIAL APPLICATIONS OF THERAPEUTIC DRUG MONITORING OF SIROLIMUS IMMUNOSUPPRESSION IN CLINICAL RENAL TRANSPLANTATION, THERAPEUTIC DRUG MONITORING 1995, 17:672-675.	
	EE	S SEHGAL, RAPAMUNE (RAPA, RAPAMYCIN, SIROLIMUS): MECHANISM OF ACTION IMMUNOSUPPRESSIVE EFFECT RESULTS FROM BLOCKADE OF SIGNAL TRANSDUCTION AND INHIBITION OF CELL CYCLE PROGRESSION, CLINICAL BIOCHEMISTRY 1998, 31:335-351.	
	EF	B KAHAN, J CHANG, S SEHGAL, PRECLINICAL EVALUATION OF A NEW POTENT IMMUNOSUPPRESSIVE AGENT, RAPAMYCIN, TRANSPLANTATION 1991, 52:185-191.	
	EG	O VILICKY, H ZOU, V MULLER, J LACHA, A SZABO and U HEEMANN, SDZ-RAD PREVENTS MANIFESTATION OF CHRONIC REJECTION IN RAT RENAL ALLOGRAFTS, TRANSPLANTATION 2000, 69:497-502.	
	EH	K NAPOLI AND B KAHAN, HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY OF RAPAMYCIN, CLINICAL CHEMISTRY 1991, 37:294-295.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8 of 8

Complete if Known**Application Number****Filing Date****First Named Inventor****Group Art Unit****Examiner Name****Attorney Docket Number**

795-A03-004

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	EI	Henderson, D.J., I. Naya, R. V. Bundick, G.M. Smith and G. A. Schmidt. 1991. Comparison of the effects of FK-506, Cyclosporin-A, and rapamycin on IL-2 production. <i>Immunology</i> 73: 316.	
	EJ	Vathsala, A., T.C. Chou, B.D. Kahan. 1990. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. <i>Transplantation</i> 49: 463.	
	EK	Kahan B.D., S. Gibbons, N. Tejpal, S.M. Stepkowski, and T.C. Chou. 1991. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. <i>Transplantation</i> 51: 232.	
	EL	Tu Y, Stepkowski SM, Chou TC, Kahan BD. The synergistic effects of cyclosporine, sirolimus and brequinor on heart allograft survival in mice. <i>Transplantation</i> 1995; 59: 177.	
	EM	Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. <i>J Immunol</i> 1995; 154: 922.	
	EN	Yakimets WJ, Lakey JR, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: rapamycin efficacy is blood level related. <i>Transplantation</i> 1993; 56: 1293.	
	EO	Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. <i>Transplantation</i> . 1995; 59: 655-661.	
	EP	Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of cell cycle. <i>Circulation</i> , 1999; 99: 2164-2170.	
	EQ	REDDY, KR, Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable Drugs, <i>The Annals of Pharmacotherapy</i> , Vol 34, pp 915-923, July/August 2000	
	ER	M. GUBA et al., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, <i>Nature Medicine</i> , Volume 8, February 2002, pp 128-135.	
	ES	M. IURLARO et al., Antiangiogenesis by cyclosporine, <i>Experimental Hematology</i> , Volume 26, 1998, pp. 1215-1222.	

Examiner
SignatureDate
Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)					
Sheet	3.	of	8	Attorney Docket Number	795-A03-004

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY
	BR	6,258,121		Yang et al.	07-10-2001
	BS	6,273,913		Wright et al.	08-14-2001
	BT	6,299,604		Ragheb	10-09-2001
	BU	6,309,380		Larson	10-30-2001
	BV	6,335,029		Kamath et al.	01-01-2002
	BW	6,344,035		Chudzik et al.	02-05-2002
	BX	6,364,903		Tseng et al.	04-02-2002
	BY	6,368,658		Schwartz et al.	04-09-2002
	BZ	6,379,382		Yang	04-30-2002
	CA	6,455,518		Zenke et al	09-24-2002
	CB	6,530,951		Bates	03-11-2003
	CC	6,545,097		Pinchuk	04-08-2003
	CD	6,585,764		Wright et al.	07-01-2003

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T ⁶
	DA	WO 98/55162 A2	Polybiomed Ltd.	12-10-1998	
	DB	WO 98/18468 A1	American Home Products	05-07-1998	
	DC	WO 98/07415 A2	Novartis AG	02-26-1996	
	DD	WO 96/04906 A1	Wellcome Foundation Ltd.	02-22-1996	

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPR Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.